Experienced in Anemia

Dr. Boone W. Goodgame

Hematology | Oncology
Seton Family Of Doctors
1601 Trinity St, Stop 804, 
Austin, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Anemia
Seton Family Of Doctors
1601 Trinity St, Stop 804, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Boone Goodgame is a Hematologist and an Oncologist in Austin, Texas. Dr. Goodgame is rated as an Experienced provider by MediFind in the treatment of Anemia. His top areas of expertise are Squamous Cell Lung Carcinoma, ALK-Positive Non-Small Cell Lung Cancer, Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Vertebroplasty. Dr. Goodgame is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Anemia.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Ascension Seton Hays
Ascension Seton Medical Center Austin
Dell Seton Med Center At The University Of Tx
Ascension Seton Northwest
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sendero
  • HMO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

SETON FAMILY OF DOCTORS
1601 Trinity St, Stop 804, Austin, TX 78712

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
View 6 Less Clinical Trials

20 Total Publications

Measuring the Unseen Burden: Immunotherapy and Targeted Therapy Reduce Treatment-Related Time Toxicity in Incurable Malignancies.
Measuring the Unseen Burden: Immunotherapy and Targeted Therapy Reduce Treatment-Related Time Toxicity in Incurable Malignancies.
Journal: World journal of oncology
Published: July 06, 2025
Similar Doctors
Distinguished in Anemia
Dr. Derrick D. Nguyen
Hematology Oncology | Oncology | Hematology
Distinguished in Anemia
Dr. Derrick D. Nguyen
Hematology Oncology | Oncology | Hematology

Scott And White Clinic

1300 E Polk St, Baylor Scott And White Clini, 
Burnet, TX 
 (44.0 miles away)
512-715-6400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Derrick Nguyen is a Hematologist Oncology specialist and an Oncologist in Burnet, Texas. Dr. Nguyen is rated as a Distinguished provider by MediFind in the treatment of Anemia. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Anemia, and Lynch Syndrome. Dr. Nguyen is currently accepting new patients.

Advanced in Anemia
Dr. Benjamin J. Downie
Oncology | Palliative Medicine | Hematology
Advanced in Anemia
Dr. Benjamin J. Downie
Oncology | Palliative Medicine | Hematology

Seton Family Of Doctors

1500 Red River St, 
Austin, TX 
 (0.1 miles away)
512-324-7000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Downie is an Oncologist and a Palliative Medicine provider in Austin, Texas. Dr. Downie is rated as an Advanced provider by MediFind in the treatment of Anemia. His top areas of expertise are Breast Cancer, Thrombocytopenia, RUNX1 Familial Platelet Disorder, and Paget Disease of the Breast. Dr. Downie is currently accepting new patients.

Advanced in Anemia
Dr. Thomas L. Aung
Oncology | Hematology Oncology
Advanced in Anemia
Dr. Thomas L. Aung
Oncology | Hematology Oncology

Texas Oncology PA

1401 Medical Pkwy, Suite 200, 
Cedar Park, TX 
 (18.2 miles away)
512-260-6050
Languages Spoken:
English, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Thomas Aung is an Oncologist and a Hematologist Oncology provider in Cedar Park, Texas. Dr. Aung is rated as an Advanced provider by MediFind in the treatment of Anemia. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Anemia, and Pleuropulmonary Blastoma. Dr. Aung is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goodgame's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 60 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile